BridgeBio LLC

84 articles with BridgeBio LLC

• BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

  5/29/2020

  BridgeBio Pharma, Inc. affiliate QED Therapeutics announced that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QED’s oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma.

• BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in AchondroplasiaData Accepted to ENDO 2020

  5/11/2020

  BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of disproportionate short stature. Data were accepted for presentation at the Endocrine Society's Annual Meeting (“ENDO 2020”), which was cancelled due to COVID-19, and the studies

• BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference in May 14, 2020

  5/6/2020

  BridgeBio Pharma, Inc. announced that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM.

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 05, 2020

  5/5/2020

  BridgeBio Pharma, Inc. announced that on May 1, 2020, the compensation committee of BridgeBio’s board of directors granted five employees options to purchase an aggregate of 39,600 shares of the Company’s common stock with a per share exercise price of $28.97 and restricted stock units for an aggregate of 18,230 shares of the Company’s common stock.

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 03, 2020

  4/3/2020

  BridgeBio Pharma, Inc. announced that on March 31, 2020, the compensation committee of BridgeBio’s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company’s common stock with a per share exercise price of $25.08 and restricted stock units for an aggregate of 22,993 shares of the Company’s common stock.

• BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

  3/12/2020

  PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations

• BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

  3/5/2020

  BridgeBio Pharma, Inc. announced the pricing of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

  3/2/2020

  BridgeBio Pharma, Inc. (NASDAQ: BBIO), today is reporting its fourth quarter and full year 2019 financial results and recent progress across its portfolio

• 

  BioSpace Movers & Shakers, Feb. 28

  2/28/2020

  Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers.

• BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

  2/22/2020

  BridgeBio Pharma, Inc., together with affiliate company Eidos Therapeutics announced that they are presenting at two upcoming investor conferences

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Feb. 05, 2020

  2/5/2020

  BridgeBio Pharma, Inc. announced that on February 3, 2020, the compensation committee of BridgeBio’s board of directors granted nine new employees options to purchase an aggregate of 96,361 shares of the Company’s common stock with a per share exercise price of $34.81 and restricted stock units for an aggregate of 23,647 shares of the Company’s common stock.

• 

  Companies Provide Business and Pipeline Updates at J.P. Morgan 2020

  1/14/2020

  With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
• 

  Clinical Catch-Up: January 6-10, 2020

  1/13/2020

  The first full business week of the new year began with plenty of clinical trial news. Here’s a look.

• BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

  1/13/2020

  New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder

• BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

  1/6/2020

  The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling

• 

  A Look at 5 Big and Interesting Biotech IPOs for 2019

  12/20/2019

  Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.

• BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

  12/18/2019

  BridgeBio Pharma, Inc. and Medison Pharma Ltd. have entered into an exclusive license agreement under which Medison received rights from Origin to distribute, market, sell and otherwise commercialize Origin’s drug product known as fosdenopterin in Israel..

• 

  Clinical Catch-Up: December 2-5

  12/9/2019

  It was, as usual, a pretty busy week in clinical trial news. Here’s a look.

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Dec. 05, 2019

  12/6/2019

  BridgeBio Pharma, Inc. announced that on November 22, 2019, the compensation committee of BridgeBio’s board of directors granted eight new employees options to purchase an aggregate of 62,745 shares of the Company’s common stock with a per share exercise price of $31.14 and restricted stock units for an aggregate of 23,980 shares of the Company’s common stock.

• CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

  11/16/2019

  AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation